Profound Medical (PROF)
(Delayed Data from NSDQ)
$8.03 USD
0.00 (0.00%)
Updated Apr 26, 2024 03:59 PM ET
After-Market: $8.17 +0.14 (1.74%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PROF 8.03 0.00(0.00%)
Will PROF be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for PROF based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PROF
Profound Medical (PROF), Siemens Unite to Treat Prostate Cancer
Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Lags Revenue Estimates
PROF: What are Zacks experts saying now?
Zacks Private Portfolio Services
Profound Medical (PROF) Soars 9.4%: Is Further Upside Left in the Stock?
How Much Upside is Left in Profound Medical (PROF)? Wall Street Analysts Think 66.06%
Strength Seen in Profound Medical (PROF): Can Its 19.5% Jump Turn into More Strength?
Other News for PROF
Profound Medical to Release First Quarter 2024 Financial Results on May 9 – Conference Call to Follow
Profound Medical Unveils Q1 2024 Financials
Profound Medical Announces Q1 2024 Results Release
Profound Medical to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference
Profound Medical to Present at Healthcare Investor Conference